PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Clinical trials for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
Disease control OngoingThis phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or sta…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: PLX038 trial launches
Disease control OngoingThis Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors a…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control OngoingThis trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
Disease control OngoingThis phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Virus therapy takes on Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC